Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study

<b>Introduction</b>: Cholera remains a major public health threat in endemic settings, and oral cholera vaccine (Shanchol™) campaigns are increasingly used amid constrained global supply. However, practical decisions on revaccination require clearer, setting-specific estimates of how rapidly vaccine-induced vibriocidal antibodies peak and wane. <b>Methods</b>: We conducted a prospective cohort kinetics analysis in Lukanga Swamps (Central Province, Zambia), enrolling adults (18-65 years) stratified by prior Shanchol™ exposure (0, 1, or 2 previous doses). All participants received two Shanchol™ doses 14 days apart, with serum collected at baseline and days 14, 28, 60, and 90 (end of follow-up). Ogawa and Inaba vibriocidal titres were measured using a complement-based assay and analysed on the log10 scale. Serotype-specific mixed-effects models with natural cubic splines for time (knots: 14, 28, 60 days) assessed trajectories by prior-dose strata, adjusting for age, sex, and HIV status. Peak timing and post-peak half-life were derived from model-based predictions with participant-level bootstrap CIs (1000 replications). <b>Results</b>: The analysis included 225 participants: 68 (30.2%) with zero prior doses, 89 (39.6%) with one, and 68 (30.2%) with two; median age was 33 years (IQR 25-49), 56.4% were female, and 19.2% were HIV-positive. Modelled titres for both serotypes rose steeply after vaccination, peaking around day 36-37 across prior-dose strata. Ogawa titres reached half of peak by about day 73-78, corresponding to post-peak half-lives of 37-41 days; Inaba declined more slowly with half-lives of 42-46 days. Confidence intervals overlapped across prior-dose strata, indicating minimal differences by vaccination history. <b>Conclusions</b>: In this cholera-endemic adult population, Shanchol™ induced vibriocidal responses that peaked at ~5 weeks and waned over the following 5-7 weeks, with broadly similar kinetics regardless of prior vaccination and slightly slower decay for Inaba than Ogawa. These parameters can inform booster timing in hotspot settings.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-01-30
DOI
https://doi.org/10.3390/vaccines14020147
Primary Topic
Vibrio bacteria research studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study

Mwelwa Chibuye, Kennedy Chibesa, Sack Da, Mutinta Muchimba et al.
Vaccines
Vibrio bacteria research studies
article

Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study

Mwelwa Chibuye, Kennedy Chibesa, Sack Da, Mutinta Muchimba, Charlie Chaluma Luchen, Fraser Liswaniso, Roma Chilengi, Bernard Phiri, Harriet Ng’ombe, Dennis Ngosa, Amanda K. Debes
article en

Abstract

<b>Introduction</b>: Cholera remains a major public health threat in endemic settings, and oral cholera vaccine (Shanchol™) campaigns are increasingly used amid constrained global supply. However, practical decisions on revaccination require clearer, setting-specific estimates of how rapidly vaccine-induced vibriocidal antibodies peak and wane. <b>Methods</b>: We conducted a prospective cohort kinetics analysis in Lukanga Swamps (Central Province, Zambia), enrolling adults (18-65 years) stratified by prior Shanchol™ exposure (0, 1, or 2 previous doses). All participants received two Shanchol™ doses 14 days apart, with serum collected at baseline and days 14, 28, 60, and 90 (end of follow-up). Ogawa and Inaba vibriocidal titres were measured using a complement-based assay and analysed on the log10 scale. Serotype-specific mixed-effects models with natural cubic splines for time (knots: 14, 28, 60 days) assessed trajectories by prior-dose strata, adjusting for age, sex, and HIV status. Peak timing and post-peak half-life were derived from model-based predictions with participant-level bootstrap CIs (1000 replications). <b>Results</b>: The analysis included 225 participants: 68 (30.2%) with zero prior doses, 89 (39.6%) with one, and 68 (30.2%) with two; median age was 33 years (IQR 25-49), 56.4% were female, and 19.2% were HIV-positive. Modelled titres for both serotypes rose steeply after vaccination, peaking around day 36-37 across prior-dose strata. Ogawa titres reached half of peak by about day 73-78, corresponding to post-peak half-lives of 37-41 days; Inaba declined more slowly with half-lives of 42-46 days. Confidence intervals overlapped across prior-dose strata, indicating minimal differences by vaccination history. <b>Conclusions</b>: In this cholera-endemic adult population, Shanchol™ induced vibriocidal responses that peaked at ~5 weeks and waned over the following 5-7 weeks, with broadly similar kinetics regardless of prior vaccination and slightly slower decay for Inaba than Ogawa. These parameters can inform booster timing in hotspot settings.

VaccinesVol. 14(2)
Centre for Infectious Disease Research in Zambia (ZM), University of Ghana (GH), Johns Hopkins University (US), Stellenbosch University (ZA), University of the Free State (ZA), Wellcome Sanger Institute (GB), University of Zambia (ZM), Amsterdam Institute for Global Health and Development (NL), National Institute of Public Administration (ZM)
Good health and well-being
Openalex Percentile: Top 69%
Vibrio bacteria research studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.